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Abstract
Objective: To determine clinically related characteristics in patients with pure lower motor neuron (LMN) syndromes, not
fulfilling accepted diagnostic criteria, who were likely to respond to intravenous immunoglobulin (IVIg) treatment.
Methods: Demographic, clinical, laboratory and neurophysiological characteristics were prospectively collected from
patients with undifferentiated isolated LMN syndromes who were then treated with IVIg. Patients were classified as either
responders or non-responders to therapy with IVIg based on clinical data and the two groups were compared.
Results: From a total cohort of 42 patients (30 males, 12 females, aged 18-83 years), 31 patients responded to IVIg and 11
did not. Compared to patients that developed progressive neurological decline, responders were typically younger (45.8
compared to 56.0 years, P,0.05) and had upper limb (83.9% compared to 63.6%, NS), unilateral (80.6% compared to 45.5%,
P,0.05), and isolated distal (54.1% compared to 9.1%, P,0.05) weakness. Patients with predominantly upper limb,
asymmetrical, and distal weakness were more likely to respond to IVIg therapy. Of the patients who responded to
treatment, only 12.9% had detectable GM1 antibodies and conduction block (not fulfilling diagnostic criteria) was only
identified in 22.6%.
Conclusions: More than 70% of patients with pure LMN syndromes from the present series responded to treatment with
IVIg therapy, despite a low prevalence of detectable GM1 antibodies and conduction block. Patients with isolated LMN
presentations, not fulfilling accepted diagnostic criteria, may respond to IVIg therapy, irrespective of the presence of
conduction block or GM1 antibodies, and should be given an empirical trial of IVIg to determine treatment responsiveness.
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Introduction
From a clinical perspective, it is often difficult to distinguish
amyotrophic lateral sclerosis (ALS) from more treatable motor
neuropathies early in the course of the illness, particularly in
patients with pure lower motor neuron (LMN) involvement. [1]
For instance, patients with multifocal motor neuropathy (MMN)
also present with lower motor neuron (LMN) syndromes, typically
with asymmetrical weakness of the distal upper limbs. Weakness
and wasting develop in the absence of objective sensory or upper
motor neuron (UMN) dysfunction. The demonstration of focal
conduction block (CB) on motor nerve conduction studies remains
the key neurophysiological hallmark of MMN, and although anti-
ganglioside antibodies (GM1 antibodies) may be detectable in a
proportion of patients, such antibodies may also be expressed in
ALS. [2]
Although often difficult in clinical practice, the distinction of
ALS and other degenerative lower motor neuron diseases from
MMN remains crucial as therapy with IVIg is likely to benefit
patients with MMN. Specifically, although MMN is rare, up to
78% of patients will improve with intravenous immunoglobulin
(IVIg) therapy, whereas patients with ALS will continue to
deteriorate. [3,4] IVIg therapy is expensive and prescription is
often restricted by regulatory authorities. In addition to common
and mild side effects such as headache, fever, and malaise, therapy
with IVIg may occasionally be complicated by nephrotoxicity, [5]
anaphylaxis, myocardial infarction, stroke or even death [6]
further supporting the general view that IVIg therapy should be
reserved for patients likely to benefit. Without treatment, patients
with MMN develop progressive weakness and functional disability,
and in such a context may be misdiagnosed as ALS. In addition,
patients with an MMN-like presentation, but without CB, may
also be initially diagnosed as ALS, although a therapeutic
treatment trial may show benefit from IVIg. [7]
The current consensus criteria for the diagnosis of MMN rely
on the demonstration of CB in two or more motor nerve segments.
[8] The criteria were designed for research use rather than clinical
practice and inevitably exclude treatable patients from the
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by the recognition of a group of patients who presented with an
ultimately treatment responsive LMN syndrome, but did not meet
the diagnostic criteria. The aim of the present study was to identify
clinical and neurophysiological characteristics using a ‘real-life’
practical approach, that may prove useful to predict IVIg response
amongst patients, to further dissect patients with a pure LMN
syndrome in routine clinical practice.
Methods
Patients with clinically isolated LMN syndromes were identified
from three specialised ALS clinics. Ethical approval for the study
was obtained from the South Eastern Sydney and Illawarra Area
Health Service Human Research Ethics Committee.
Patients were included in the study if they presented with an
undifferentiated isolated LMN syndrome, that did not meet the
accepted criteria for either a degenerative motor neuron disease or
an inflammatory motor neuropathy (eg MMN or chronic
inflammatory demyelinating polyneuropathy) and had received
induction treatment with induction IVIg treatment (0.4 g/kg per
day for 5 consecutive days) followed by at least three monthly
maintenance treatments (0.4 g/kg by single infusion per month).
Patients were studied consecutively and data recorded prospec-
tively. Demographic data, symptom duration, presence and
pattern of weakness (i.e. distal, proximal or mixed), the presence
of wasting, and pattern of onset (unilateral or bilateral, upper limb
or lower limb) were all recorded. Therapy was continued until the
response to treatment had become clear and, in practice, this often
entailed months of maintenance treatment. Treatment was ceased,
at the discretion of the treating physician, in patients who
deteriorated despite ongoing IVIg treatment, usually due to the
development of more typical features of ALS such as UMN signs
or bulbar involvement.
The study exclusion criteria were objective sensory deficits or
abnormalities on standard sensory nerve conduction studies,
marked UMN signs such as pathological hyper-reflexia (defined
as exaggerated reflexes elicited with minimal stimulus or spread of
reflexes) or an alternative diagnosis. Specifically, patients with
chronic inflammatory demyelinating polyneuropathy, or benign
focal amyotrophy were excluded from the study. [9,10] Patients
with suspected Hirayama’s disease underwent cervical MRI in
neck flexion, [11] and if the diagnosis was confirmed, were
excluded.
Standard clinical investigations and GM1 antibodies were
recorded in each patient. Neurophysiological data such as distal
compound motor action potential (CMAP) amplitudes and the
detection of CB was recorded. Standard neurophysiological
investigations were undertaken using an Oxford Teca Synergy
machine (Oxford Instruments, Old Woking, Manor Way, UK).
Patients had bilateral studies of upper and lower limb nerves
including the median, ulnar (with above and below elbow
stimulations), common peroneal and tibial motor nerves, with
results compared to laboratory normal and published control
values. [12] CB was defined in accordance with the consensus
criteria for the diagnosis of MMN, [8] such that definite CB was
indicated by a reduction in CMAP amplitude of .50% in distal
median, distal ulnar or proximal peroneal nerve segments, or
.60% in a distal peroneal or tibial nerve segments. CB across
common sites of entrapment were not included in the analysis.
Probable CB was noted when an amplitude reduction of 40–49%
in median and ulnar nerve segments or 50–59% in distal peroneal
or tibial nerve segments was detected. In addition, abnormal
amplitude reduction (AAR), defined as 30–40% amplitude
reduction in median, ulnar and radial nerve segments, or 40–
50% amplitude reduction in distal common peroneal and tibial
nerve segments was recorded. The detection of electromyographic
discharges, fibrillation and fasciculation potentials was also noted.
By convention, the frequency of fibrillation potentials recorded in
each muscle were graded on a scale from 0 to 4 (0 – None; 1 –
persistent fibrillation potentials in at least two areas; 2 – moderate
numbers of persistent fibrillation potentials; 3 – large numbers of
persistent fibrillation potentials; 4 – profuse, widespread, persistent
fibrillation potentials which fill the baseline). [13] The individual
muscle grades were summed and divided by the number of
muscles studies to determine a novel fibrillation score per muscle
for each patient.
Response to treatment was determined clinically through a
combination of clinical history and examination findings on follow-
up, the latter with reference to any improvement, stabilisation or
deterioration in motor power as graded by the medical research
council (MRC) grading scales [14] after treatment. Patients who
improved or stabilised with IVIg treatment were classified as
responders and those who deteriorated in terms of power testing as
non-responders. As mentioned, the development of upper motor
neuron signs or bulbar dysfunction, or clinical progression
suggestive of ALS, was noted and indicated non-response to
treatment. Although all patients received a minimum of three
months of IVIg therapy, treatment was continued until such time as
the clinical outcome had become clear.
Statistical analysis, with P,0.05 considered significant, was
performed by application of the chi-square, paired t and Mann-
Whitney tests as required (Statistical Package for Social Sciences
17.0, SPSS Inc; Chicago, IL, USA). In order to compare
categorical data (for example proximal/mixed weakness compared
to distal weakness), 262 tables were constructed and the Chi-
square test applied. A receiver operator curve (ROC) was
constructed using the fibrillation score to plot the true positive
rate (y axis) and the false positive rate (x axis) of a candidate
investigation. This process was utilised to establish a threshold at
which the both the sensitivity and specificity of the investigation
were maximal.
Results
In total, 42 patients were eligible for the study (30 males, 12
females, mean age 48.4 +/- 13.9 years, range 18 to 83 years), and
patients were included over a period of 10 years. Mean follow-up
duration was 35 +/- 32 months (range 3 to 136 months). After
treatment with IVIg, 31 patients were classified as responders; 11
patients as non-responders and later fulfilled the criteria for a
diagnosis of ALS. During the study period, two non-responders
died of ALS-related complications. All responders continued to
receive monthly maintenance IVIg infusions and no significant
complications of IVIg treatment were encountered.
Clinical phenotype
The demographic and clinical characteristics of responders and
non-responders are presented in Table 1. The mean age of
responders was significantly less (45.8 +/- 13.4 years) than non-
responders (56.0 +/- 13.1 years, P,0.05). Median symptom
duration prior to diagnosis was longer in responders (18 months)
than non-responders (12 months, NS), as was mean symptom
duration at first assessment (responders 46.8 +/- 72.3; non-
responders 18.2 +/- 20.2, NS). On average, responders had
symptoms for 46.8 months prior to treatment, and several
responders had symptoms for years before receiving treatment
with IVIg.
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groups, although a minority of patients presented with wasting,
muscle cramps or pain. Although severity of muscle wasting did
not differ between responders and non-responders, the two
patient groups had different patterns of weakness. For example,
54.8% of responders had isolated distal upper limb weakness
rather than proximal or mixed weakness, compared to on 9.1%
of non-responders (P,0.05). Unilateral onset was more common
in responders than non-responders (P,0.05) (Figure 1). Re-
sponders also tended to have upper rather than lower limb
symptom onset, and had fewer limbs involved at the time of
presentation when compared to non-responders. There was no
correlation between the degree of limb wasting and treatment
outcome.
Clinical investigations
Results of clinical investigations are summarised in Table 2.
GM1 (IgM class) antibodies were identified in 12.9% of responders
and definite CB (not reaching diagnostic criteria for MMN) was
identified in 22.6% of responders, but more than 50% of
responders had no evidence of GM1 antibodies or CB. When
detected, CB was identified in the ulnar nerve (3 patients), the
median nerve (2 patients), the common peroneal nerve (1 patient)
and the tibial nerve (1 patient). Neither GM1 antibodies nor CB
Table 1. Demographic and clinical characteristics.
Responders Non-responders P value
Number of Patients 31 11
Average Age (years +/- SD) 45.8 +/-13.4 56.0 +/-13.1 ,0.05
Male Gender (% pts) 22 (71%) 8 (73%) NS
Median Symptom Duration (months) 18 12
Mean Symptom Duration at First Assessment (months +/- SD) 46.8 +/- 72.3 18.2 +/- 20.2 NS
Follow-up Duration (months +/- SD) 41.6 (+/-34.9) 16.9 (+/-9.0) ,0.05
Number of involved limbs (+/- SD) 1.5 (+/-0.6) 2.1 (+/-1.3) NS
Degree of Wasting
None or mild 19 (61.3%) 6 (54.5%) NS
Marked 12 (38.7%) 5 (45.5%)
Pattern of Weakness
Upper limb 26 (83.9%) 7 (63.6%) NS
Unilateral 25 (80.6%) 5 (45.5%) ,0.05
Distal 17 (54.8%) 1 (9.1%) ,0.05
The demographic and clinical features of 42 patients who presented with an isolated LMN syndrome. Responders were younger than non-responders, and typically had
distal, asymmetrical, upper limb weakness.
doi:10.1371/journal.pone.0027041.t001
Figure 1. Responders (white bars) had the typical clinical phenotype of MMN, namely upper limb, unilateral, and distal onset
weakness.
doi:10.1371/journal.pone.0027041.g001
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without definite CB, 6.5% had probable CB and a further 12.9%
had ARR, which was also detected in 36.4% of non-responders. In
total, 41.9% of responders had CB or ARR compared to 36.4%
non-responders, but the difference was not significant. By
combining GM1 antibodies with CB and ARR to identify
responders sensitivity improved (41.9%), but the specificity
deteriorated (36.4%).
The distal CMAP amplitudes at the initial assessment did not
differ significantly between responders and non-responders overall
(Table 2) and initial distal CMAP amplitudes did not predict
treatment outcome. However, non-responders demonstrated
progressive decline in CMAP amplitudes on progress nerve
conduction studies, suggestive of secondary axonal loss. Using
electromyography, fasciculation potentials were common in both
groups, but fibrillation potentials, positive sharp waves and
complex repetitive discharges were more frequent in non-
responders than responders, perhaps indicating more aggressive
denervation (i.e. likely ALS). An ROC was constructed to
determine the fibrillation score threshold which identified non-
responders at an optimal sensitivity and specificity (Figure 2).
Using this approach, a fibrillation score of .0.4 was determined to
identify non-responders with moderate sensitivity (64%) and
specificity (62%).
Discussion
The present cohort of forty-two patients who presented with an
isolated LMN syndrome has identified that the most reliable
predictor of a positive IVIg treatment response, and key
distinguishing feature from ALS, was the recognition of the
typical clinical phenotype of MMN, namely an upper limb,
unilateral, and distal onset pattern of weakness. Diagnostic criteria
for MMN remain insensitive and would have excluded the
majority of responders in this series from a therapeutic trial of
therapy. Apart from CB and GM1 antibodies, detected in a
minority of responders, no neurophysiological or laboratory
characteristic reliably distinguished responders from non-respond-
ers, with the latter progressing to a diagnosis of ALS. The present
study supports the view that patients who present with isolated
LMN syndromes should be given an empirical trial of IVIg
therapy early in the course of their illness to determine treatment
responsiveness.
Due to the lack of demonstrable CB, more than half of the
responders in the present series did not satisfy the consensus
criteria for the diagnosis of MMN. Nonetheless, responders
exhibited a similar clinical phenotype to published cohorts of
Table 2. Neurophysiological Characteristics.
Responders Non-responders P value
Number of Patients 31 11
GM1 antibodies IgM + (% pts) 4 (12.9%) 0 NS
Distal CMAP at initial assessment (mean mV +/- SD)
Upper limb 7.3 +/-2.7 8.2 +/-2.3 NS
Lower limb 6.6 +/-3.9 4.3 +/-2.7 NS
Overall 7.0 +/-2.4 6.4 +/-2.2 NS
Definite CB (% pts) 22.6% 0.0% NS
Definite or Probable CB (% pts) 29.0% 0.0% NS
Definite CB, Probable CB or ARR (% pts) 41.9% 36.4% NS
Electromyography (% pts)
Fibrillations 61.3% 81.8% NS
Complex repetitive discharges 22.6% 36.4% NS
Fasciculations 45.2% 36.4% NS
The laboratory and clinical neurophysiological characteristics of 42 patients who presented with an isolated LMN syndrome. GM1 antibodies and conduction block (CB),
although only identified in responders, were detected in less than half of all responders.
doi:10.1371/journal.pone.0027041.t002
Figure 2. A receiver operator curve (ROC) was constructed to
identify the fibrillation score cut-off that identified non-
responders with the maximal sensitivity while preserving
specificity. Sensitivity is represented on the y axis and (1-specificity)
on the x axis. The asterisk (*) indicates a fibrillation score of 0.4. A
score.0.4 detected non-responders with moderate sensitivity (64%)
and specificity (62%).
doi:10.1371/journal.pone.0027041.g002
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MMN may be too strict and thus exclude patients with MMN
based on an absence of detectable CB. Weakness among
responders progressed insidiously, as reflected by symptom
durations prior to first assessment, and was predominately upper
limb, unilateral, and distal in onset. Responders were younger
than non-responders, and as others have observed [17,20,21],
many responders in the present series had symptoms for several
years prior to treatment, often after review by several neurologists.
Although not useful in selecting patients for IVIg treatment early
in the course of their illness, slow progression of disease over many
months or years may allow the distinction of ALS from other
conditions. [22] Early intervention in such cases might lead to
improved treatment outcomes and potentially reduced long term
disability due to secondary axonal loss. If, after early initiation of
therapy, patients develop typical features of ALS, such as UMN
signs or bulbar involvement, withdrawal of IVIg would be
appropriate. Such an approach is becoming the de facto standard
of care in many major ALS centres.
The presence of detectable GM1 antibodies was highly specific
for a positive treatment response to IVIg, but only 12.9% of
responders in this series were positive for GM1 antibodies. This
rate is similar to that documented for patients with LMN
syndromes treated with IVIg [20], but lower than in cohorts of
MMN. [17,18] Although the reported sensitivity of GM1
antibodies remains highly variable, GM1 titres have recently been
correlated with the severity of weakness in MMN. [23]
Definite or probable CB on standard motor nerve conduction
studies was highly specific, but poorly sensitive, for response to
IVIg treatment. The relatively low rate of detectable CB in the
present series is similar to cohorts of MMN patients. [17,19] When
smaller CMAP amplitude reductions (i.e. ARR) were included in
the analysis, the sensitivity improved marginally, but specificity
dropped dramatically. Even after including CB, ARR and GM1
antibodies only 45.2% of responders were identified.
Undetected proximal CB among responders in the present
series cannot be excluded, as cervical root stimulation was not
universally performed. However, cervical root stimulation tech-
niques are technically demanding, and their use in previous studies
has yielded variable results. [19,24] As such, the role of these
techniques has not been definitively established. Other techniques,
for example utilising transcranial magnetic stimulation may detect
proximal CB [25], or conversely, may detect sub-clinical UMN
dysfunction in ALS patients. [26,27] Given the difficulty in
detecting proximal CB using neurophysiological techniques, T2
weighted magnetic resonance imaging is recommended by the
European Federation Neurological Societies / Peripheral Nerve
Society guidelines to establish proximal involvement – such as
proximal demyelination or nerve root hypertrophy – in MMN or
other immune mediated neuropathies. [28,29]
In summary, the presence of CB or GM1 antibodies are specific
but insensitive predictors of response to IVIg in patients that
present with isolated LMN syndromes that do not meet diagnostic
criteria for degenerative motor neuron diseases or inflammatory
motor neuropathy. Responders may have slowly progressive
symptoms for many years prior to starting treatment, that may
detrimentally affect the therapeutic outcome. Given that the
present cohort may be considered relatively small, a larger
randomised placebo control trial would be required to definitively
establish the role of IVIg in patients with pure LMN syndromes
that do not fulfil diagnostic criteria. Nonetheless, the present study
supports the view that patients with pure LMN syndromes should
be given an early therapeutic trial of IVIg, even in the absence of
GM1 antibodies and CB.
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